Literature DB >> 23649622

Mechanism of endogenous regulation of the type I interferon response by suppressor of IκB kinase epsilon (SIKE), a novel substrate of TANK-binding kinase 1 (TBK1).

James D Marion1, Charlotte F Roberts, R Jason Call, Jonathan L Forbes, Kristina T Nelson, J Ellis Bell, Jessica K Bell.   

Abstract

TANK-binding kinase 1 (TBK1) serves as a key convergence point in multiple innate immune signaling pathways. In response to receptor-mediated pathogen detection, TBK1 phosphorylation promotes production of pro-inflammatory cytokines and type I interferons. Increasingly, TBK1 dysregulation has been linked to autoimmune disorders and cancers, heightening the need to understand the regulatory controls of TBK1 activity. Here, we describe the mechanism by which suppressor of IKKε (SIKE) inhibits TBK1-mediated phosphorylation of interferon regulatory factor 3 (IRF3), which is essential to type I interferon production. Kinetic analyses showed that SIKE not only inhibits IRF3 phosphorylation but is also a high affinity TBK1 substrate. With respect to IRF3 phosphorylation, SIKE functioned as a mixed-type inhibitor (K(i, app) = 350 nM) rather than, given its status as a TBK1 substrate, as a competitive inhibitor. TBK1 phosphorylation of IRF3 and SIKE displayed negative cooperativity. Both substrates shared a similar Km value at low substrate concentrations (∼50 nM) but deviated >8-fold at higher substrate concentrations (IRF3 = 3.5 μM; SIKE = 0.4 μM). TBK1-SIKE interactions were modulated by SIKE phosphorylation, clustered in the C-terminal portion of SIKE (Ser-133, -185, -187, -188, -190, and -198). These sites exhibited striking homology to the phosphorylation motif of IRF3. Mutagenic probing revealed that phosphorylation of Ser-185 controlled TBK1-SIKE interactions. Taken together, our studies demonstrate for the first time that SIKE functions as a TBK1 substrate and inhibits TBK1-mediated IRF3 phosphorylation by forming a high affinity TBK1-SIKE complex. These findings provide key insights into the endogenous control of a critical catalytic hub that is achieved not by direct repression of activity but by redirection of catalysis through substrate affinity.

Entities:  

Keywords:  Cooperativity; Enzyme Inhibitors; Enzyme Kinetics; Enzyme Mechanisms; Innate Immunity

Mesh:

Substances:

Year:  2013        PMID: 23649622      PMCID: PMC3690000          DOI: 10.1074/jbc.M112.440859

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  Multiple regulatory domains control IRF-7 activity in response to virus infection.

Authors:  R Lin; Y Mamane; J Hiscott
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

2.  IKK-i and TBK-1 are enzymatically distinct from the homologous enzyme IKK-2: comparative analysis of recombinant human IKK-i, TBK-1, and IKK-2.

Authors:  Nandini Kishore; Q Khai Huynh; Sumathy Mathialagan; Troii Hall; Sharon Rouw; David Creely; Gary Lange; James Caroll; Beverley Reitz; Ann Donnelly; Hymavathi Boddupalli; Rodney G Combs; Kuniko Kretzmer; Catherine S Tripp
Journal:  J Biol Chem       Date:  2002-02-11       Impact factor: 5.157

3.  IkappaB kinases alpha and beta show a random sequential kinetic mechanism and are inhibited by staurosporine and quercetin.

Authors:  G W Peet; J Li
Journal:  J Biol Chem       Date:  1999-11-12       Impact factor: 5.157

4.  Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling.

Authors:  Misako Matsumoto; Satomi Kikkawa; Masayoshi Kohase; Kensuke Miyake; Tsukasa Seya
Journal:  Biochem Biophys Res Commun       Date:  2002-05-24       Impact factor: 3.575

5.  mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties.

Authors:  Dong-chul Kang; Rahul V Gopalkrishnan; Qingping Wu; Eckhard Jankowsky; Anna Marie Pyle; Paul B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

6.  Kinetic mechanisms of IkappaB-related kinases (IKK) inducible IKK and TBK-1 differ from IKK-1/IKK-2 heterodimer.

Authors:  Q Khai Huynh; Nandini Kishore; Sumathy Mathialagan; Ann M Donnelly; Catherine S Tripp
Journal:  J Biol Chem       Date:  2002-01-28       Impact factor: 5.157

7.  Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-kappaB-dependent gene transcription.

Authors:  M Bonnard; C Mirtsos; S Suzuki; K Graham; J Huang; M Ng; A Itié; A Wakeham; A Shahinian; W J Henzel; A J Elia; W Shillinglaw; T W Mak; Z Cao; W C Yeh
Journal:  EMBO J       Date:  2000-09-15       Impact factor: 11.598

8.  NAK is an IkappaB kinase-activating kinase.

Authors:  Y Tojima; A Fujimoto; M Delhase; Y Chen; S Hatakeyama; K Nakayama; Y Kaneko; Y Nimura; N Motoyama; K Ikeda; M Karin; M Nakanishi
Journal:  Nature       Date:  2000-04-13       Impact factor: 49.962

9.  Structure and ubiquitination-dependent activation of TANK-binding kinase 1.

Authors:  Daqi Tu; Zehua Zhu; Alicia Y Zhou; Cai-hong Yun; Kyung-Eun Lee; Angela V Toms; Yiqun Li; Gavin P Dunn; Edmond Chan; Tran Thai; Shenghong Yang; Scott B Ficarro; Jarrod A Marto; Hyesung Jeon; William C Hahn; David A Barbie; Michael J Eck
Journal:  Cell Rep       Date:  2013-02-28       Impact factor: 9.423

10.  Identification of the minimal phosphoacceptor site required for in vivo activation of interferon regulatory factor 3 in response to virus and double-stranded RNA.

Authors:  Marc J Servant; Nathalie Grandvaux; Benjamin R tenOever; Delphine Duguay; Rongtuan Lin; John Hiscott
Journal:  J Biol Chem       Date:  2003-01-10       Impact factor: 5.157

View more
  9 in total

Review 1.  STRIPAK complexes in cell signaling and cancer.

Authors:  Z Shi; S Jiao; Z Zhou
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

2.  The IKK-related kinase TBK1 activates mTORC1 directly in response to growth factors and innate immune agonists.

Authors:  Cagri Bodur; Dubek Kazyken; Kezhen Huang; Bilgen Ekim Ustunel; Kate A Siroky; Aaron Seth Tooley; Ian E Gonzalez; Daniel H Foley; Hugo A Acosta-Jaquez; Tammy M Barnes; Gabrielle K Steinl; Kae-Won Cho; Carey N Lumeng; Steven M Riddle; Martin G Myers; Diane C Fingar
Journal:  EMBO J       Date:  2017-11-17       Impact factor: 11.598

3.  Predicting and validating a model of suppressor of IKKepsilon through biophysical characterization.

Authors:  Megan L Machek; Halie A Sonnenschein; Sasha-Kaye I Graham; Flowreen Shikwana; Seung-Hwan L Kim; Selena Garcia DuBar; Ian D Minzer; Ryan Wey; Jessica K Bell
Journal:  Protein Sci       Date:  2019-05-23       Impact factor: 6.725

4.  Identification of 1H-pyrazolo[3,4-b]pyridine derivatives as novel and potent TBK1 inhibitors: design, synthesis, biological evaluation, and molecular docking study.

Authors:  Yin Sun; Haotian Tang; Xiaoyan Wang; Fang Feng; Tiantian Fan; Dongmei Zhao; Bing Xiong; Hua Xie; Tongchao Liu
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

5.  Suppressor of IKKɛ is an essential negative regulator of pathological cardiac hypertrophy.

Authors:  Ke-Qiong Deng; Aibing Wang; Yan-Xiao Ji; Xiao-Jing Zhang; Jing Fang; Yan Zhang; Peng Zhang; Xi Jiang; Lu Gao; Xue-Yong Zhu; Yichao Zhao; Lingchen Gao; Qinglin Yang; Xue-Hai Zhu; Xiang Wei; Jun Pu; Hongliang Li
Journal:  Nat Commun       Date:  2016-06-01       Impact factor: 14.919

6.  ERRα negatively regulates type I interferon induction by inhibiting TBK1-IRF3 interaction.

Authors:  Xiang He; Shengli Ma; Yinyin Tian; Congwen Wei; Yongjie Zhu; Feng Li; Pingping Zhang; Penghao Wang; Yanhong Zhang; Hui Zhong
Journal:  PLoS Pathog       Date:  2017-06-07       Impact factor: 6.823

7.  Suppressor of IKKepsilon forms direct interactions with cytoskeletal proteins, tubulin and α-actinin, linking innate immunity to the cytoskeleton.

Authors:  Halie A Sonnenschein; Kenneth F Lawrence; Karli A Wittenberg; Frank A Slykas; Emerald L Dohleman; Jilan B Knoublauch; Sean M Fahey; Timothy M Marshall; James D Marion; Jessica K Bell
Journal:  FEBS Open Bio       Date:  2018-06-19       Impact factor: 2.693

8.  Combinatorial targeting of Hippo-STRIPAK and PARP elicits synthetic lethality in gastrointestinal cancers.

Authors:  Liwei An; Zhifa Cao; Pingping Nie; Hui Zhang; Zhenzhu Tong; Fan Chen; Yang Tang; Yi Han; Wenjia Wang; Zhangting Zhao; Qingya Zhao; Yuqin Yang; Yuanzhi Xu; Gemin Fang; Lei Shi; Huixiong Xu; Haiqing Ma; Shi Jiao; Zhaocai Zhou
Journal:  J Clin Invest       Date:  2022-05-02       Impact factor: 19.456

9.  Prognostic values of inhibitory κB kinases mRNA expression in human gastric cancer.

Authors:  David Timothy Gayed; Jayant Wodeyar; Zi-Xiang Wang; Xiang Wei; Yi-Yi Yao; Xiao-Xi Chen; Zhou Du; Ji-Cai Chen
Journal:  Biosci Rep       Date:  2019-01-15       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.